

# Clinical, genetic and microbiological characterization of pediatric patients with Cystic Fibrosis in a Public Hospital in Ecuador

**Yazmina Lascano-Vaca**

Hospital Carlos Andrade Marin

**Esteban Ortiz-Prado** (✉ [e.ortizprado@gmail.com](mailto:e.ortizprado@gmail.com))

Universidad de Las Américas <https://orcid.org/0000-0002-1895-7498>

**Lenin Gomez-Barreno**

OneHealth research group Universidad de Las Americas Facultad de Ciencias de la Salud

**Katherine Simbaña-Rivera**

OneHealth Global research Group, Universidad de las Americas

**Eduardo Vasconez**

OneHealth Global research Group, Universidad de las Americas

**Alexander Lister**

University of Southampton Faculty of Medicine

**María Emilia Arteaga-Espinosa**

Genetic department, Gynemedic

**Geovanny F Perez**

Children's National Health System

---

## Research article

**Keywords:** Cystic Fibrosis, epidemiological analysis, clinical characterization

**Posted Date:** February 28th, 2020

**DOI:** <https://doi.org/10.21203/rs.2.12767/v4>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License. [Read Full License](#)

---

**Version of Record:** A version of this preprint was published at BMC Pediatrics on March 6th, 2020. See the published version at <https://doi.org/10.1186/s12887-020-2013-6>.

## Abstract

**Background:** To carry out a complete clinical, pathological, genetic and microbiological characterization of pediatric patients with molecular confirmed cystic fibrosis (CF) attending the Carlos Andrade Marín Hospital (HCAM) within the study period.

**Methods:** A cross-sectional analysis of the pediatric population with a confirmed diagnosis of CF disease who attended HCAM, one of the largest tertiary-level hospitals in Ecuador, between 2017 and 2018 was performed. All demographic, clinical and genetic variables were obtained from the electronic medical records (EMR) stored by the hospital.

**Results:** 47 patients with CF were included in the study. Gender distribution was similar between male (48.9%, n = 23) and female patients (51.1%, n = 24). The Tiffeneau-Pinelli index (FEV<sub>1</sub> /FVC) changed significantly after nine months post-diagnosis (85.55 ± 13.26; p < 0.05). The most common pathogenic genetic variants were F508del, found in 52.78% of the cohort (n = 19); H609R, found in 36.11% (n = 13); g.204099A>C, found in 14.1% (n = 7), followed by G85E and the N1303K with 11.11% (n = 3) each.

**Conclusions:** To our best knowledge, this is the first study exploring the clinical, genetic and bacteriological profile of CF's patients in Ecuador. Within the cohort of patients, an important and unique genetic feature was characterized by the presence of the g.204099A> C and the c.206359C>A homozygous polymorphism as well as the presence of the H609R variant, a mutation only reported among Ecuadorians.

## Introduction

Cystic fibrosis (CF) is an autosomal recessive disorder caused by a variant in a gene located on the long arm of chromosome 7. The affected gene is the cystic fibrosis transmembrane regulator (*CFTR*), which when mutated produces an abnormal production of the cystic fibrosis transmembrane regulator protein (1–3). This condition affects many organ systems within the body (4–7), with a clinical presentation potentially including progressive obstructive lung disease, bronchitis, bronchiectasis, mild to severe pancreatic insufficiency, malnutrition and recurrent sinusitis, with infertility also being common in men (7, 8).

CF has become an important public health problem. It has a great impact in terms of healthcare-related costs and on the years of potential life lost (PYLL), resulting in an economic burden for health systems globally (9–12). CF is one of the most common and lethal genetic diseases, affecting an estimated 70,000 patients from all ethnic groups worldwide (8). The incidence ranges from 1:2,000 to 1:35,000 in newborns, representing more than 1,000 new cases of CF that are diagnosed each year before the age of two (7, 8, 12, 13). Universal newborn screening and early treatment have markedly improved median survival rates in high-income countries (HIC) in comparison to low- and middle-income countries (LMIC) (12, 14–16). In countries like the United States, Canada and some European countries, average survival curves have improved in the last 30 years, with some patients reaching life expectancies of 50 years or more (17–20). On the other hand, patients from LMICs often have poorer health outcomes, living on average 10 to 15 years less than individuals with CF from HICs (15, 20, 21). Zolin *et al.* revealed that mortality among younger patients (under 18 years of age) reaches 1.3% in LMIC and less than 0.6% in high-middle income countries (HMICs) (22). In Latin America, most of the children presenting with related symptoms are misdiagnosed or not diagnosed at all, usually leading to early deaths before reaching the first five years of age (16). In Latin America, CF's incidence ranges from 1:6,000 to 1:12,000 per every live birth. For instance, Mexico has an incidence of 1:9,000, Uruguay at 1:9,600 and in Argentina an estimation of 1:6,573 per every live birth (23).

In Ecuador, there has been few academic studies on CF. An analysis from Valle *et al.* (24) determined for the first time, the incidence of the disease in the country at 1:11,252 live births (24). Although there are a few reports of CF in Ecuador, there are no detailed reports including diagnostic, microbiologic and genetic analysis, as well as pulmonary function data, as recommended by international guidelines such as the North American Cystic Fibrosis Foundation (25–27).

The objective of this study was to conduct a complete clinical, pathological, genetic and microbiological characterization of pediatric patients with molecular confirmed CF attending the Carlos Andrade Marín Hospital within the study period.

## Methodology

*Study design:*

A cross-sectional study of pediatric patients with confirmed cystic fibrosis from the tertiary-level hospital, Carlos Andrade Marín (HCAM), was performed. The data included information from all available aspects of the patients' charts recorded between June 2017 to July 2018.

#### *Setting:*

This study was conducted in the largest capacity hospital of the Social Security Institute (IESS). The HCAM has a clinic system with a multidisciplinary team specialized in management of CF, who receive referrals and admissions from the nearby provinces and cities. The hospital is located in Quito, the capital of Ecuador. During the study period, the clinic received 81 patients, pediatric and adult, with diagnosis of cystic fibrosis.

#### *Participants:*

A total of 48 individuals aged 16 or younger with a confirmed diagnosis of cystic fibrosis (positive sweat test accompanied a pathological genetic variant report) were approached for inclusion in this study. One child whose parents did not consent to participate was excluded from the study, leading to 47 pediatric patients being included for analysis. It is important to emphasize that there were two pairs of siblings within the study.

#### *Treatment:*

Throughout the study, all patients had the same standard treatment protocol that included: respiratory therapy with inhaled Dornase Alfa and hypertonic saline twice daily, respiratory physiotherapy with prolonged slow expiratory and forced expiratory techniques, and digestive enzymes according to weight to all patients with stool elastase less than 200. For patients with *Pseudomonas* bacteria colonization, tobramycin through inhalation was administered twice daily for 28 days. All additional interventions due to exacerbations were described in the results section.

#### *Ethical Considerations:*

Informed consent was obtained from every patient and their parents or their legal representatives after disclosing the full purpose of the study. All data were anonymized before further analysis through assigning a study reference number between one and forty-seven, allocated upon patient presentation. The local Institutional Review Board at HCAM approved this study in 2017.

#### *Data:*

Demographic, clinical and analytic variables were obtained by reviewing electronic medical records (EMR) from all the patients included in the study in a 12-month period. Demographic information was obtained for analysis, which included the patient's age, gender, ethnicity, place of residence and educational attainment level. Clinical parameters included family and personal medical history, respiratory/gastrointestinal symptomatology and Shwachman - Kulczycki (SK) disease severity score. The SK scores were considered in the categories of 'excellent' (86–100), 'good' (71–85), 'mild' (56–70), 'moderate' (41–55), or 'severe' disease severity ( $\leq 40$ ). Follow-up was conducted through ongoing scheduled clinician appointments at the hospital. Analytical tests were performed to evaluate pulmonary function using a Spirometer (CareFusion Germany 234 GmbH software) following the ATS/ERS standard criteria. Forced Vital Capacity (FVC), Forced Expiratory Volume in One Second ( $FEV_1$ ) and  $FEV_1/FVC$  measurements were used for statistical analysis. In addition, microbiological cultures and sensitivity tests were conducted in every patient. Those children under five years of age had deep throat cultures taken, and for children over five years of age, sputum samples were used to evaluate microbiological colonization. Finally, all patients were analyzed for *CFTR* gene variants by polymerase chain reaction

(PCR) and Sanger sequencing by cycling temperature capillary electrophoresis of a panel of 10 specific *CFTR* common variants for the Ecuadorian population. Also, 13 patients had *CFTR* full-length sequencing analysis, which was processed in the United States. Since the full-length sequencing tests were not available in Ecuador and the exportation of the samples were not covered by the public insurance, some patients were not able to obtain the resources to proceed with the full sequence.

#### *Statistical Analysis:*

Data were analyzed using the software SAS (Version 9.3; SAS Institute Inc., Cary, NC, USA). Patients were categorized into four subgroups: <5 years, 5 to 9 years, 10 to 14 years old and 15 years old. Descriptive statistics, such as simple frequencies and means, were used to calculate demographic distribution, clinical findings, cultures and sensitivity of germs, and genetic profiles. For pulmonary function, statistics calculated were a parametric test with Shapiro-Wilk formula and a paired t-test for related samples to evaluate the deterioration of pulmonary function. Statistical significance was determined at  $p < 0.05$ .

## **Results**

#### *Demographics:*

Out of 48 pediatric patients that fulfilled the inclusion criteria, 47 were included since one patient withdrew the consent. The sex distribution corresponded to 24 females and 23 males. Age distribution at study period demonstrated that 27.7% ( $n = 13$ ) were under five years, 23.4% ( $n = 11$ ) were between five and nine years, 31.9% ( $n = 15$ ) were between 10 and 14 years and 17.0% ( $n = 8$ ) of patients were 15 years or older, with a median age of 9.2 years (SE  $\pm 4.98$  years). The maximum age was 16 years. In the case of age of diagnosis referred by parents, it was found an age of 5.3 years (SE  $\pm 5.26$  years). Overall, 89.4% ( $n = 42$ ), 6.4% ( $n = 3$ ) and 4.3% ( $n = 2$ ) of patients were auto-identified as mixed race, white and indigenous, respectively.

#### *Clinical Variables:*

A total of 41 (87.2%) children were referred to the hospital for diagnosis due to persistent respiratory symptoms (cough, recurrent pneumonia, dyspnea on exertion and chest pain). Six patients (12.8%) were referred with persistent gastrointestinal symptoms (including abdominal distention, increased frequency of stools, flatulence or steatorrhea). These symptoms were present at the time of diagnosis, and it was because of these symptoms the individuals had been referred to the hospital for diagnosis. Four patients (8.5%) had positive family history of the disease (Table 1).

Nutritional evaluation included body mass index (BMI) and percentile tables. Malnutrition was found in 25.5% ( $n = 12$ ) of children with the females showing a median BMI of 17.4  $\text{kg}/\text{m}^2$  (percentile 42nd; z-score -0.42) and males showing an average BMI of 15.8  $\text{kg}/\text{m}^2$  (percentile 28th; z-score -0.87). Patients not recorded as malnourished had a median BMI that was around the 38<sup>th</sup> percentile (z-score -0.62). The Shwachman – Kulczycki score analysis at diagnosis demonstrated that almost half of the patients (44.7%,  $n = 21$ ) had scores of 'excellent', followed by 'good', 'mild' and 'moderate' scores in 27.66% ( $n = 13$ ), 25.5% ( $n = 12$ ) and 2.1% ( $n = 1$ ) respectively. Furthermore, no "severe scores" were reported. Asthma was present in 25.5% ( $n = 12$ ) of cases, followed by CF-related diabetes in 8.5% ( $n = 4$ ), meanwhile allergic bronchopulmonary aspergillosis was reported in 6.4% ( $n = 3$ ).

Throughout the study period, a total of 14.9% ( $n = 7$ ) patients had exacerbations that required hospital management with clinicians, with an average of 2.5 hospitalizations per patient and an average inpatient stay of 18 days. Finally, during this study period, there were no deaths reported among the patients.

#### *Pulmonary Function:*

Pulmonary function tests were indicated in 28 patients (59.6%). At diagnosis, spirometry showed values of  $\text{FEV}_1$  with a mean of 92.67% pred. (SD =  $\pm 16.95$ ), FVC with a mean of 100.81% pred. (SD =  $\pm 15.37$ ) and  $\text{FEV}_1/\text{FVC}$  with a mean of 89.81 (SD =  $\pm 7.69$ ).

When comparing the difference between FEV<sub>1</sub> pulmonary function at diagnosis (baseline) and at follow-up, values show at three months follow-up a non-significant drop in FEV<sub>1</sub> (Mean = 88.87 ± 22.33; p >0.05) as well as at six months follow-up (Mean = 89.04 ± 27.66; p >0.05) and a significant drop at nine months (Mean = 86.40 ± 24.80; p <0.05). In addition, follow-up mean difference comparison of FVC at three months follow-up was a non-significant drop (Mean = 98.65 ± 18.75; p >0.05) and at six months (Mean = 97.04 ± 22.91; p >0.05), with a significant drop in FVC at nine months (Mean = 95.77 ± 18.94; p <0.05) (Figure 1).

The differences in pulmonary function by age group and follow-up visit are displayed in Table 2.

Figure 1 Spirometry results from baseline up to 9 months follow-up in patients from Ecuador

\* FEV<sub>1</sub>/FVC is measured in percentage, while FVC and FEV<sub>1</sub> are expressed in percentage of the predicted value.

The comparison among different times relative to the mean differences in FEV<sub>1</sub>/FVC at three (Mean = 87.86 ± 9.36; p >0.05), six (Mean = 87.89 ± 11.63; p >0.05) and nine months (Mean = 85.55 ± 13.26; p <0.05) is displayed in table 2.

### Microbiology:

Bacteriological cultures and antibiograms were obtained every three months after the date of diagnosis. The most common isolated organism was *Staphylococcus aureus* (oxacillin sensitive) in 25.9% of the samples, followed by *Haemophilus influenzae* in 17.7% and *Pseudomonas aeruginosa* in 12.5%. Age group analysis showed *Haemophilus influenzae* as the most common pathogen in patients younger than 10 years, while *Moraxella Catarrhalis* decreased in frequency in patients older than 10 years. *Staphylococcus aureus* (oxacillin sensitive and resistant) and *Pseudomonas aeruginosa* became more common in patients older than 10 years (Figure 2).

Figure 2 Presence of different microorganism per age group according to the bacteriological culture results

A total of 120 susceptibility tests were performed; four species of gram-positive bacteria (*S. aureus*, *Coagulase-Negative Staphylococcus*, *Streptococcus pneumoniae* and *M. catarrhalis*) were the most common, with *S. aureus* showing the largest frequency (n = 95) among cultures, being most of them highly susceptible to sulfas, vancomycin, linezolid and ciprofloxacin while erythromycin was not effective (resistant) in most cases. Other cultures reported several types of gram-negative organisms, while only 10% of the isolate's cultures reported gram-positive organisms (Table 3). The less common pathogens found among cultures were *Acinetobacter spp*, *Achromobacter spp*, *Serratia spp* and *Raultella planticola*. These microorganisms were found only once; therefore, susceptibility tests were not performed. The most frequent gram-negative pathogen was *Pseudomonas spp*, found in 29.2% of cultures. *Pseudomonas spp* were susceptible to Cefepime, Ceftazidime, Meropenem, Imipenem and Piperacillin/Tazobactam, but showed resistance in almost 20% of cases against Amikacin and Gentamicin, as well as Ciprofloxacin in less than 10% of isolated cultures. *Haemophilus spp* was found in 16.7% of tests, with the bacteria demonstrating high sensitivity to Ampicillin/Sulbactam, Azithromycin, Ceftriaxone and Cefuroxime, however, was resistant to Co-trimoxazole and Ampicillin in less than 50% and 15% of tests respectively. *Enterobacter spp* was isolated in 10.8% of the samples and showed to be highly sensitive to Ceftazidime and Gentamicin as well as to Ceftriaxone and Piperacillin/Tazobactam (Table 3).

### Genetic Analysis:

The genetic tests were comprehensively compared and correlated with the information available from the ClinVar and the Single Nucleotide Polymorphism (dbSNP) databases (Table 4). Among children attending HCAM, 36 out of 47 patients underwent *CFTR* sequence analysis. A total of 23 patients had a specifically targeted variant panel, and 13 of them had full-length gene sequencing.

The most common pathogenic variant reported was F508del, found in 52.8% (n = 19) of tested patients. The variant was found in homozygous state in four patients and in heterozygous state in 15 patients. The second most common variant reported was H609R, found in 13 patients (36.1%), most of them in heterozygous state (n = 11), while homozygous state was only found among

indigenous patients, and may be related to a founder effect (36). The third most common pathogenic variants were G85E and N1303K, both found in 11.1% of the patients. Less common variants included the W1098X, G542X and the R170H (Table 5).

We found some variants that had already been reported in previous reports and also some not previously reported, including g.204099A>C in 19.4% (n = 7), followed by M470V in 16.7% (n = 6), c.869+11C>T in 11.1% (n = 4) and the g.206359C>A in 11.1% (n = 4) of cases. Finally, the less commonly reported variants were the g.19395G>A, c.164+12T>C, Q1463\* and other particular variants as shown in Table 5.

### *Ecuadorian Genetic Profile*

Seven patients who were compound heterozygous for different variants also had other multiple allelic combinations never seen before, such as the g.204099A>C polymorphism, in the seven of them in homozygous state. This polymorphism g.204099A>C has only been reported in Ecuadorian populations to date, establishing its role as a predisposing genetic factor in positive cases. (Table 6).

## **Discussion**

CF is an autosomal recessive disorder seen worldwide, with typically a higher prevalence in Caucasian populations (11). A significant problem in developing countries is that CF patients have a shorter life expectancy, with many patients diagnosed at a later stage in life once symptoms of the disease have manifested (28). This study has shown that the average age of diagnosis is after the age of nine, with only 38.3% of patients diagnosed before five years of age. Later stage diagnosis is common among developing countries, while in high-income countries, more than 95% of the patients are diagnosed during the first year of life (11, 29).

In the sample of patients, respiratory symptoms (cough, recurrent pneumonia, dyspnea on exertion and chest pain) were most commonly described, followed by gastrointestinal symptoms including abdominal distention, increased frequency of stools, flatulence and steatorrhea. The clinical presentation in Ecuadorian patients appears to be similar to those reports from other Latin-American countries (23, 30). As often reported, BMI values are often low, and malnutrition has manifested. In our analysis, we found that the patients had an average BMI of 16.6 kg/m<sup>2</sup>, with girls showing greater average BMI values (17.4 kg/m<sup>2</sup>) compared to the boys (15.8 kg/m<sup>2</sup>). Culhane *et al.* reported higher BMI values for girls being slightly lower (21 kg/m<sup>2</sup>) than boys (22 kg/m<sup>2</sup>), probably due to increased energy losses, increased energy needs or differences in inadequate calorie intake among boys (31). Despite the later diagnosis of the disease, malnutrition was presented in only a quarter of our patients. The Shwachman-Kulczycki scores of 'good' or 'excellent' were seen in more than 70% of patients. This grading system is often used to track progress in these types of patients (32, 33).

In terms of comorbidities, a diagnosis of asthma in CF patients is difficult due to overlapping respiratory symptoms presenting in patients. Around 20-30% of the patients with CF can have a concomitant clinical diagnosis of Asthma in population studies (34, 35). Our results show that 33% of our patients had this comorbidity, which is compatible with previous works.

The FEV<sub>1</sub>, FVC and the Tiffeneau-Pinelli index were within the normal range in the majority of patients. Mild lower airway obstruction was seen in all age groups, which is an interesting finding since lung function would have been expected to be lower in patients with a delayed CF diagnosis, as reported elsewhere (33). Lung function during follow-up at nine months post-diagnosis was shown to be preserved, which was likely related to the quality of management, which includes correct antibiotic management and appropriate clinical follow-up schemes (36).

Preventing complications is essential for this type of disease management. Periodical cultures had proven to be an important clinical step to take when looking to prevent further complications and implement early treatment when needed. In our report, the most common microorganism reported was *Staphylococcus aureus*, with varying antibiotic sensitivity profiles. The main differences were displayed in terms of age groups, showing a lower incidence of *Moraxella catharralis* and *Haemophilus influenzae* among cultures from patients over 10 years, while these patients had an increase in the number of positive cultures for *S. aureus*

and *Pseudomonas aeruginosa*, an observation previously reported elsewhere (37). The presence of *P. aeruginosa* within the respiratory tract is often used as a positive marker for severity among children and adults with CF (38, 39). This type of infection accelerates lung-function deterioration and increases the cost of treatments (40, 41). In our results, *P. aeruginosa* was detected in 12.5% of airway cultures, and those patients were treated immediately with a double regimen of broad-spectrum intravenous (IV) antibiotics.

An important finding of our report was the presence of the H609R variant (caused by the transition of adenosine to guanine at nucleotide 1958 - exon 13). To our best knowledge, this type of variant has only been reported among Andeans' offspring, as a likely damaging variant (27, 42–44). Among the 13 patients (38.23%) with a complete sequence, only two patients displayed a homozygous state, while six had a compound heterozygous profile with the presence of the F508del variant (27,44).

The other variants had been previously described in Ecuadorian patients with CF (27,44). Nefzi *et al.* analyzed Latin American CF patients and found four common variants: F508del (31.37%), G542X (1.96%), G85E (1.96%) and N1303K (1.96%), with 63.7% of Ecuadorian CF variants remaining unidentified (42). In the second report, in order of frequency, the variants reported were F508del (37.1%), G85E (8.9%), G542X (2.4%), N1303K (2.4%), with a detection rate of 53.22% of the total of CF patients studied. All four of these variants were found in our tested patients in the following detection percentage: 52.77%, 5.56%, 11.11%, and 11.11%, respectively.

*CFTR* exhibits an important allelic heterogeneity, a situation in which different variants in the same gene produce variations in clinical manifestations, with this heterogeneity known to be related to ethnic origin, as we can exemplify with H609R variant which has only reported in Hispanic offspring (27, 42–44). The other common variants G542X, G85E and N1303K have been consistently found in Ecuadorian patients, with frequencies greater than that of Caucasian variant panels.

In seven of the patients, the polymorphism c.204099A>C was reported, all in homozygous state, this polymorphism has been reported only in Ecuadorian populations (27), with most of these patients also showing known pathological variants. This combination of polymorphisms and variants show a variety of phenotypes in patients, such as nutritional compound, microbiological cultures, respiratory spirometry values or as a combined effect. As Polizzi *et al.* described, there is a direct relation between phenotype with the specific variant panel (45). The most severe cases with c.204099A>C polymorphism were between 10-15 years old and related to H609R and F508del/W1098X variants. In one of these patients, a poor nutrition status was seen, and in the second there were complications associated with respiratory deterioration. In addition, Moya *et al.* found in H609R homozygous Ecuadorian patients a severe clinical presentation of CF (44). This contrasts with our first patient that had a heterozygous alteration with an important nutritional implication. Sebro *et al.* described F508del in the heterozygous compound, which showed a statistical association between variant and sweat chloride level, pancreatic function and *Pseudomonas* infection risk (46), also seen in our study. Finally, CFTR2 databases describe that patients with the W1098X variant have a predictive value in the range 62 - 100% (47), which was also present in our patient. The previous studies did not include patients that were included in this study, as it was confirmed with the patient and their carers that participation in past studies had not taken place.

In four of our patients, the polymorphism c.206359C>A was reported in homozygous state. All were related to F508del/W1098X, G85E/H609R, and G970S variants, however, the first case was described in combination with c.204099A>C polymorphism as opposed to c.206359C>A. In the second patient, there was no marked nutritional alteration, with sweat testing measures showing a low value, the respiratory function was partially conserved, and only one hospital admission was seen. Decaesteker *et al.* describe that patients with G85E had a significantly higher sweat chloride, higher prevalence of pancreatic insufficiency, worse current weight for height and higher prevalence of chronic *P. aeruginosa* colonization. However, these findings are not highly concordant with our patient (45). The last case demonstrated slight malnutrition, common bacteria colonization for the age and normal respiratory function. Therefore, there was phenotypic concordance, but there were no studies available about the clinical involvement of G970S variant in the available literature.

During genetic analysis there was a unique case with variant c.204099A>C and c.206359C>A in combination with benign polymorphism M470V. This patient showed only sweat test positive, but there was no malnutrition, microbiological alteration nor complications during the study period. However, sequential spirometry test results were unavailable due to the participant's age. M470V has been described as a benign polymorphism with slight respiratory problems and recurrence, which does not show on positive on sweat test (48). The unique presence of that polymorphism combination (c.204099A>C, c.206359C>A and 470V), in

addition to the unexpected positive sweat test, make this case a unique opportunity for further investigation and follow-up in order to find more information about its phenotype expression, its management and its prognosis.

#### *Bias:*

Selection bias was present as only cases who gave informed consent were included. Every eligible pediatric CF patient was approached; however only those patients that agreed alongside parents or guardians who agreed to participate were involved in the study. This was a single location study, so results may not be generalizable for the whole Ecuadorian population. Information bias was reduced by using standardized medical records from the hospital, which were reviewed by two researchers to reduce any errors in reporting and were transcribed in two different databases that later were reconciled. Any discrepancies between the two reviewers were escalated to the study lead researcher for a resolving discussion. Diagnostic bias was reduced through only including patients with a confirmation of CF through a positive sweat test as well as genetic confirmation in the study.

#### *Limitations:*

This study was not exempt from limitations. Patients were sampled from one hospital in Ecuador; therefore, a complete extrapolation to the entire Ecuadorian population might be inaccurate. To have a better understanding of the clinical, genetic and microbiological features of CF in Ecuador, a larger sample size, over multiple hospitals around the country would be needed. Another limitation was the access to funding and equipment. Due to the lack of resources and finance, only 36 of the 47 patients underwent a genetic analysis, a selection that was allocated on a first-come, first-served basis, a decision made according to the presence of available funding. In addition, the lack of a quality asthma research center made it difficult for doctors to test for bronchial hypersensitivity according to international standards, tests that would have been valuable for this type of research.

## Conclusions

To our best knowledge, this is the first study exploring the clinical, genetic and bacteriological profile of CF's patients in Ecuador. Due to the lack of universal screening in the country, a large proportion of individuals are being diagnosed or misdiagnosed later than expected, jeopardizing their treatments and prognosis. The bacteriological results demonstrated that *S. aureus* was the most common pathogen found within the cultures, most of them showing susceptibility to sulfas, vancomycin, linezolid and ciprofloxacin.

Lastly, the current cohort of patients showed an important and unique genetic feature characterized by the presence of the g.204099A> C and the c.206359C>A homozygous polymorphism, as well as the presence of the H609R variant, a mutation only reported among Andean dwellers.

## Abbreviations

BMI = Body Mass Index

CF = Cystic Fibrosis

CFTR = cystic fibrosis transmembrane regulator

dbSNP = Single Nucleotide Polymorphism Database

EMR = Electronic Medical Records

FEV<sub>1</sub> = Forced Expiratory Volume in One Second

FVC = Forced Vital Capacity

HCAM = Carlos Andrade Marin Hospital

HIC = High Income Countries

IV = Intravenous

IESS = Ecuadorian Institute of Social Security

LMIC = Low- and Middle-Income Countries

PCR = Polymerase Chain Reaction

REGLAFQ = Registro Latinoamericano de Fibrosis Quística

SK = Shwachman – Kulczycki

## Declarations

### Availability of Data and Materials:

The datasets used during the current study are available from the corresponding author on reasonable request. His email is [e.ortizprado@gmail.com](mailto:e.ortizprado@gmail.com).

### Ethics approval and consent to participate:

The study was approved by the Institutional Review Board at HCAM through the Quipux System with the number No.- HECAM-10-2018-00##. The study participants were patients who received medical care at the hospital, and all of the information was anonymized for this publication. The patients received the standard of care for children with CF and written informed consent was routinely obtained from their parents when performing genetic testing and pulmonary function tests.

### Consent to publish:

Not Applicable

### Competing interests:

All authors declare not having any conflict of interest.

### Funding:

The publication fee for this manuscript was paid by the Research Department of Universidad de las Americas, Quito, Ecuador

### Authors' Contributions:

Researcher YLV developed the specific study idea, she conducted the clinical interviews, and she was fully in charge of the follow-up. She was fully responsible for retrieving information from the health records. EOP acted as project lead and was responsible for the conceptualization of the manuscript, preliminary data analysis and wrote the primary draft of the manuscript. LGB and KSR performed the statistical and data analysis, created the tables and figures and contribute with the final draft of the manuscript. EV was responsible for interpreting some of the information from the medical records as well as interpret bacteriological reports while AL assisted in the structuring of this information within the report. EV and AL also contributed to the structuring of the final draft of the manuscript. EAE was responsible for interpreting the genetic results and for writing them down in the manuscript. GFP was responsible for the critical review of the manuscript, the final draft of the text, and he provided critical inputs on the interpretation of the overall results and the elaboration of the manuscript.

### Acknowledgements:

We would like to thank Netlab in Ecuador for providing genetic testing at no cost to some of the patients who were not able to afford it.

### Funding

This work did not receive any funding.

## References

1. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science*. 1989;245(4922):1066–1073.
2. Knowlton RG, Cohen-Haguenaer O, Van Cong N, Frézal J, Brown VA, Barker D, et al. A polymorphic DNA marker linked to cystic fibrosis is located on chromosome 7. *Nature*. 1985;318(6044):380.
3. Zielenski J, Rozmahel R, Bozon D, Kerem B, Grzelczak Z, Riordan JR, et al. Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. *Genomics*. 1991;10(1):214–228.
4. Bobadilla JL, Macek M, Fine JP, Farrell PM. Cystic fibrosis: A worldwide analysis of CFTR mutations? correlation with incidence data and application to screening. *Human Mutation*. junio de 2002;19(6):575-606.
5. Stallings VA, Stark LJ, Robinson KA, Feranchak AP, Quinton H, on Growth CPG, et al. Evidence-based practice recommendations for nutrition-related management of children and adults with cystic fibrosis and pancreatic insufficiency: results of a systematic review. *Journal of the American Dietetic Association*. 2008;108(5):832–839.
6. Feigelson J, Anagnostopoulos C, Poquet M, Pecau Y, Munck A, Navarro J. Liver cirrhosis in cystic fibrosis—therapeutic implications and long term follow up. *Archives of disease in childhood*. 1993;68(5):653–657.
7. Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. *Nature Reviews Disease Primers*. May 2015;1:15010.
8. Spoonhower KA, Davis PB. Epidemiology of Cystic Fibrosis. *Clinics in Chest Medicine*. March 2016;37(1):1-8.
9. Davis PB. Cystic fibrosis since 1938. *American journal of respiratory and critical care medicine*. 2006;173(5):475–482.
10. Potter BK, Khangura SD, Tingley K, Chakraborty P, Little J. Translating rare-disease therapies into improved care for patients and families: what are the right outcomes, designs and engagement approaches in health-systems research? *Genetics in Medicine*. February 2016;18(2):117-23.
11. McCabe LL, Therrell BL, McCabe ERB. Newborn screening: rationale for a comprehensive, fully integrated public health system. *Molecular genetics and metabolism*. December 2002;77(4):267-73.
12. Tuchman LK, Schwartz LA, Sawicki GS, Britto MT. Cystic Fibrosis and Transition to Adult Medical Care. *PEDIATRICS*. March 2010;125(3):566-73.
13. Stephenson AL, Sykes J, Stanojevic S, Quon BS, Marshall BC, Petren K, et al. Survival Comparison of Patients With Cystic Fibrosis in Canada and the United States. *Annals of Internal Medicine*. April 2017;166(8):537.
14. Quittner AL, Schechter MS, Rasouliyan L, Haselkorn T, Pasta DJ, Wagener JS. Impact of Socioeconomic Status, Race, and Ethnicity on Quality of Life in Patients With Cystic Fibrosis in the United States. *Chest*. March 2010;137(3):642-50.
15. Goss CH, Sykes J, Stanojevic S, Marshall B, Petren K, Ostrenga J, et al. Comparison of Nutrition and Lung Function Outcomes in Patients with Cystic Fibrosis Living in Canada and the United States. *American Journal of Respiratory and Critical Care Medicine*. March 2018;197(6):768-75.
16. Kabra SK, Kabra M, Shastri S, Lodha R. Diagnosing and managing cystic fibrosis in the developing world. *Paediatric Respiratory Reviews*. January 2006;7:S147-50.
17. Óscar Fielbaum C. Avances en fibrosis quística. *Revista Médica Clínica Las Condes*. March 2011;22(2):150-9.
18. Knapp EA, Fink AK, Goss CH, Sewall A, Ostrenga J, Dowd C, et al. The Cystic Fibrosis Foundation Patient Registry. Design and Methods of a National Observational Disease Registry. *Annals of the American Thoracic Society*. July 2016;13(7):1173-9.
19. Keogh RH, Szczesniak R, Taylor-Robinson D, Bilton D. Up-to-date and projected estimates of survival for people with cystic fibrosis using baseline characteristics: A longitudinal study using UK patient registry data. *Journal of Cystic Fibrosis*. March 2018;17(2):218-27.
20. Burgel P-R, Bellis G, Olesen H V, Viviani L, Zolin A, Blasi F, et al. Future trends in cystic fibrosis demography in 34 European countries. *European Respiratory Journal*. July 2015;46(1):133-41.
21. Martínez M. Fibrosis quística en Ecuador. *NEUMOLOGIA PEDIATRICA*. 2010;5(1):51.

22. Zolin A, Bossi A, Cirilli N, Kashirskaya N, Padoan R. Cystic Fibrosis Mortality in Childhood. Data from European Cystic Fibrosis Society Patient Registry. *Int J Environ Res Public Health* [Internet]. September 2018 [Cited 28 October 2019];15(9). Available at: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6163251/>
23. Silva Filho LVRF, Castañón C, Ruíz HH. Cystic fibrosis in Latin America—Improving the awareness. *Journal of Cystic Fibrosis*. 2016;15(6):791–793.
24. Valle ÉP, Burgos RI, Valle JR, Egas Béjar D, Ruiz-Cabezas J-C. Analysis of CFTR gene mutations and Cystic Fibrosis incidence in the Ecuadorian population. *Investigacion clinica*. 2007;48(1).
25. Paz-Y-Miño C, Guillen Sacoto MJ, Leone PE. Genetics and genomic medicine in Ecuador. *Molecular genetics & genomic medicine*. January 2016;4(1):9-17.
26. González-Andrade F. Standardized clinical criteria and sweat test combined as a tool to diagnose Cystic Fibrosis. *Heliyon*. diciembre de 2018;4(12):e01050.
27. Ortiz SC, Aguirre SJ, Flores S, Maldonado C, Mejía J, Salinas L. Spectrum of CFTR gene mutations in Ecuadorian cystic fibrosis patients: the second report of the p.H609R mutation. *Molecular genetics & genomic medicine*. 2017;5(6):751-7.
28. Farrell PM, Rosenstein BJ, White TB, Accurso FJ, Castellani C, Cutting GR, et al. Guidelines for Diagnosis of Cystic Fibrosis in Newborns through Older Adults: Cystic Fibrosis Foundation Consensus Report. *The Journal of Pediatrics*. August 2008;153(2):S4-14.
29. Farrell PM, White TB, Ren CL, Hempstead SE, Accurso F, Derichs N, et al. Diagnosis of cystic fibrosis: consensus guidelines from the Cystic Fibrosis Foundation. *The Journal of pediatrics*. 2017;181:S4–S15.
30. Gale S, Sabillón M, Ortega Iglesias JC. Caracterización de los pacientes con Fibrosis Quística diagnosticados por cloruros en Sudor. *Act Ped Hond*. April 2017;6(2):486-92.
31. Culhane S, George C, Pearo B, Spoede E. Malnutrition in Cystic Fibrosis: a review. *Nutr Clin Pract*. 2013;28(6):676-83.
32. Stollar F, Villac F, Cunha M, Leone C, Rodrigues J. Shwachman-Kulczycki score still useful to monitor cystic fibrosis severity. *Clinics (Sao Paulo)*. 2011;66(6):979-83.
33. Olivo P, Flores O, Rosero C. Correlación de los valores espirométricos con el puntaje clínico de Shwachman y el puntaje radiológico de Brasfield, en la evaluación a pacientes con diagnóstico de fibrosis quística, atendidos en consulta externa del Hospital “Eugenio Espejo” de Quito, año 2014. *Rev Fac Cien Med*. 2014;39(2):25-30.
34. Kent B, Lane S, Van Beek E, Dodd J, Costello R, Tiddens H. Asthma and cystic fibrosis: a tangled web. *Pediatr Pulmonol*. 2014;49(3):205-13.
35. Weinberger M, Abu-Hasan M. Pseudo-asthma: when cough, wheezing, and dyspnea are not asthma. *Pediatrics*. 2007;120(4):855–864.
36. Wagener J, Elkin E, Pasta D, Schechter M, Konstan M, Morgan W. Pulmonary function outcomes for assessing cystic fibrosis care. *Journal of Cystic Fibrosis*. 2015;14(3):376-83.
37. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2017 Annual Data Report. Bethesda, Maryland; 2017.
38. Nixon GM, Armstrong DS, Carzino R, Carlin JB, Olinsky A, Robertson CF, et al. Clinical outcome after early *Pseudomonas aeruginosa* infection in cystic fibrosis. *J Pediatr*. May 2001;138(5):699-704.
39. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. *Pseudomonas aeruginosa* and other predictors of mortality and morbidity in young children with cystic fibrosis. *Pediatric pulmonology*. 2002;34(2):91–100.
40. Baumann U, Stocklossa C, Greiner W, von der Schulenburg J-MG, von der Hardt H. Cost of care and clinical condition in paediatric cystic fibrosis patients. *Journal of Cystic Fibrosis*. 2003;2(2):84–90.
41. Doring G, Conway SP, Heijerman HG, Hodson ME, Hoiby N, Smyth A, et al. Antibiotic therapy against *Pseudomonas aeruginosa* in cystic fibrosis: a European consensus. *European Respiratory Journal*. 2000;16(4):749–767.
42. Schrijver I, Pique L, Graham S, Pearl M, Cherry A, Kharrazi M. The Spectrum of CFTR Variants in Nonwhite Cystic Fibrosis Patients: Implications for Molecular Diagnostic Testing. *The Journal of Molecular Diagnostics*. January 2016;18(1):39-50.
43. Keyeux G, Rodas C, Bienvenu T, Garavito P, Vidaud D, Sanchez D, et al. CFTR mutations in patients from Colombia: Implications for local and regional molecular diagnosis programs. *Human Mutation*. 2003;22(3):259-259.

44. Moya-Quiles MR, Glover G, Mondéjar-López P, Pastor-Vivero MD, Fernández-Sánchez A, Sánchez-Solís M. CFTR H609R mutation in Ecuadorian patients with cystic fibrosis. *J Cyst Fibros.* July 2009;8(4):280-1.
45. Polizzi A, Tesse R, Santostasi T, Diana A, Manca A, Logrillo VP, et al. Genotype-phenotype correlation in cystic fibrosis patients bearing [H939R;H949L] allele. *Genetics and Molecular Biology.* 2011;34(3):416-20.
46. Sebros R, Levy H, Schneck K, Dimmock D, Raby BA, Cannon CL, et al. Cystic fibrosis mutations for p.F508del compound heterozygotes predict sweat chloride levels and pancreatic sufficiency. *Clinical genetics.* December 2012;82(6):546.
47. CFTR2 Variant Search | CFTR2 [Internet]. [Cited 28 October 2019]. Available at: <https://www.cftr2.org/mutation/general/W1098X/>
48. Çelik T, Güneşçar R, Balcı A, Ünal S, Aldic G, Eskici H, et al. The Importance of the M470V Polymorphism. *BUCH* [Internet]. 2017 [Cited 28 October 2019]; Available at: <http://www.behcetuzdergisi.com/jvi.asp?pdire=behcetuz&plng=eng&un=BUCHD-59254&look4=>

## Tables

Table 1 Clinical findings reported among patients with CF in Ecuador

| <b>Clinical findings reported at CF Diagnosis</b> |                   |                    |                     |                 |
|---|-------------------|--------------------|---------------------|-----------------|
|   | <b>&lt; 5 (%)</b> | <b>6 to 10 (%)</b> | <b>11 to 15 (%)</b> | <b>≥ 16 (%)</b> |
| <b>Number of individuals (n)</b>                  |                   |                    |                     |                 |
| Familiar history with asymptomatic patient        | 13                | 11                 | 15                  | 8               |
|   | 15.4              | 9.1                | 6.7                 | 0.0             |
| <b>Symptoms</b>                                   |                   |                    |                     |                 |
| Persistent respiratory symptoms                   | 69.2              | 90.9               | 93.3                | 100.0           |
| Persistent gastrointestinal symptoms              | 38.5              | 0.0                | 6.7                 | 0.0             |
| <b>Signs</b>                                      |                   |                    |                     |                 |
| Digital clubbing                                  | 0.0               | 27.3               | 13.3                | 25.0            |
| Abnormal liver function test                      | 7.7               | 0.0                | 0.0                 | 0.0             |
| Sinus disease                                     | 0.0               | 9.1                | 6.7                 | 25.0            |
| Malnutrition                                      | 23.1              | 18.2               | 33.3                | 25.0            |
| Body mass index percentile (average)              | *44.8             | *37.6              | *37.8               | *28.3           |
| <b>Score Shwachman – Kulczycki</b>                |                   |                    |                     |                 |
| Excellent   | 53.9              | 63.6               | 33.3                | 25.0            |
| Good  | 46.1              | 27.3               | 20.0                | 12.5            |
| Mild  | 0.0               | 9.1                | 46.7                | 50.0            |
| Moderate  | 0.0               | 0.0                | 0.0                 | 12.5            |
| Severe  | 0.0               | 0.0                | 0.0                 | 0.0             |
| <b>Comorbidities</b>                              |                   |                    |                     |                 |
| Cystic fibrosis related Diabetes                  | 0.0               | 0.0                | 6.7                 | 37.5            |
| Asthma  | 0.0               | 36.4               | 40.0                | 25.0            |
| Pulmonary Hypertension                            | 0.0               | 0.0                | 6.7                 | 12.5            |
| Celiac disease                                    | 0.0               | 0.0                | 6.7                 | 0.0             |
| Cholelithiasis                                    | 0.0               | 0.0                | 6.7                 | 0.0             |
| Allergic bronchopulmonary aspergillosis           | 0.0               | 9.1                | 13.3                | 0.0             |
| Pancreatitis                                      | 0.0               | 18.2               | 0.0                 | 0.0             |
| Meconium ileus/other intestinal obstruction       | 0.0               | 9.1                | 6.7                 | 0.0             |

\* Values expressed in average

Table 2 Pulmonary function among Ecuadorian patients with CF divided in three age groups

| Age group              | Follow-up    | FEV1 %pred. (SD) | FVC %pred. (SD) | FEV1/FVC (SD) |
|------------------------|--------------|------------------|-----------------|---------------|
| 5 to 9 years (n =11)   | At diagnosis | 105,3 (13.1)     | 106,3 (15.9)    | 98,5 (8.2)    |
|                        | 3-month      | 95,8 (27.2)      | 100,8 (22.3)    | 92,5 (10.9)   |
|                        | 6-month      | 104,7 (30.7)     | 109,4 (25.3)    | 93,7 (11.9)   |
|                        | 9-month      | 105,3 (29.5)     | 107,0 (23.5)    | 95,3 (10.9)   |
| 10 to 14 years (n =15) | At diagnosis | 87,7 (12.8)      | 97,5 (11.5)     | 87,9 (4.3)    |
|                        | 3-month      | 87,1 (20.9)      | 97,0 (18.5)     | 88,0 (6.6)    |
|                        | 6-month      | 86,6 (22.7)      | 94,1 (20.1)     | 88,0 (8.3)    |
|                        | 9-month      | 80,4 (18.3)      | 92,3 (16.3)     | 81,7 (11.9)   |
| ≥ 15 years (n =8)      | At diagnosis | 90,4 (19.9)      | 99,6 (18.3)     | 87,6 (8.0)    |
|                        | 3-month      | 85,8 (22.3)      | 100,0 (18.2)    | 83,0 (11.6)   |
|                        | 6-month      | 76,9 (31.9)      | 90,1 (25.3)     | 72,8 (29.4)   |
|                        | 9-month      | 79,3 (25.8)      | 91,3 (17.2)     | 83,8 (15.1)   |

\*FEV1 (Forced expiratory ventilation at first second) and FVC (Forced vital capacity) are expressed as a percentage of the predicted values (% pred.), while FEV1/FVC is expressed in percentage.

Table 3 Bacteriological culture results from Ecuadorian patients with CF

|                         | Microorganisms                    | Isolations (n)          | Antibiotics             | Susceptibility (n) | Susceptibility (%) | Resistance (n) | Resistance (%) | Non-described (n) | Non-described (%) |
|-------------------------|-----------------------------------|-------------------------|-------------------------|--------------------|--------------------|----------------|----------------|-------------------|-------------------|
| Gram-positive           | Staphylococcus aureus             | 95                      | Ciprofloxacin           | 55                 | 57.89              | 4              | 4.21           | 36                | 37.89             |
|                         |                                   |                         | Clindamycin             | 46                 | 48.42              | 38             | 40.00          | 11                | 11.58             |
|                         |                                   |                         | Erythromycin            | 19                 | 20.00              | 61             | 64.21          | 15                | 15.79             |
|                         |                                   |                         | Gentamicin              | 64                 | 67.37              | 15             | 15.79          | 16                | 16.84             |
|                         |                                   |                         | Linezolid               | 55                 | 57.89              | 0              | 0.00           | 40                | 42.11             |
|                         |                                   |                         | Oxacillin               | 40                 | 42.11              | 39             | 41.05          | 16                | 16.84             |
|                         |                                   |                         | Co-trimoxazole          | 74                 | 77.89              | 1              | 1.05           | 20                | 21.05             |
|                         |                                   |                         | Vancomycin              | 51                 | 53.68              | 0              | 0.00           | 44                | 46.32             |
|                         | Coagulase-Negative Staphylococcus | 3                       | Clindamycin             | 0                  | 0.00               | 2              | 66.67          | 1                 | 33.33             |
|                         |                                   |                         | Gentamicin              | 2                  | 66.67              | 0              | 0.00           | 1                 | 33.33             |
|                         |                                   |                         | Erythromycin            | 0                  | 0.00               | 2              | 66.67          | 1                 | 33.33             |
|                         |                                   |                         | Oxacillin               | 1                  | 33.33              | 1              | 33.33          | 1                 | 33.33             |
|                         |                                   |                         | Penicillin              | 0                  | 0.00               | 2              | 66.67          | 1                 | 33.33             |
|                         |                                   |                         | Co-trimoxazole          | 2                  | 66.67              | 0              | 0.00           | 1                 | 33.33             |
|                         | Streptococcus pneumoniae          | 7                       | Ceftriaxone             | 4                  | 57.14              | 0              | 0.00           | 3                 | 42.86             |
|                         |                                   |                         | Clindamycin             | 2                  | 28.57              | 1              | 14.29          | 4                 | 57.14             |
|                         |                                   |                         | Penicillin              | 4                  | 57.14              | 2              | 28.57          | 1                 | 14.29             |
|                         |                                   |                         | Co-trimoxazole          | 2                  | 28.57              | 3              | 42.86          | 2                 | 28.57             |
|                         | Corynebacterium spp               | 2                       | Doxycycline             | 1                  | 50.00              | 0              | 0.00           | 1                 | 50.00             |
|                         |                                   |                         | Levofloxacin            | 1                  | 50.00              | 0              | 0.00           | 1                 | 50.00             |
|                         | Gram negatives                    | Escherichia coli        | 11                      | Amikacin           | 6                  | 54.55          | 3              | 27.27             | 2                 |
| Ampicillin/sulbactam    |                                   |                         |                         | 0                  | 0.00               | 8              | 72.73          | 3                 | 27.27             |
| Cefepime                |                                   |                         |                         | 1                  | 9.09               | 9              | 81.82          | 1                 | 9.09              |
| Ceftazidime             |                                   |                         |                         | 1                  | 9.09               | 9              | 81.82          | 1                 | 9.09              |
| Ciprofloxacin           |                                   |                         |                         | 1                  | 9.09               | 7              | 63.64          | 3                 | 27.27             |
| Gentamicin              |                                   |                         |                         | 4                  | 36.36              | 4              | 36.36          | 3                 | 27.27             |
| Imipenem                |                                   |                         |                         | 10                 | 90.91              | 0              | 0.00           | 1                 | 9.09              |
| Piperacillin/tazobactam |                                   |                         |                         | 4                  | 36.36              | 3              | 27.27          | 4                 | 36.36             |
| Enterobacter spp        |                                   | 13                      | Ceftazidime             | 10                 | 76.92              | 0              | 0.00           | 3                 | 23.08             |
|                         |                                   |                         | Ceftriaxone             | 8                  | 61.54              | 0              | 0.00           | 5                 | 38.46             |
|                         |                                   |                         | Gentamicin              | 10                 | 76.92              | 0              | 0.00           | 3                 | 23.08             |
|                         |                                   |                         | Piperacillin/tazobactam | 8                  | 61.54              | 0              | 0.00           | 5                 | 38.46             |
| Haemophilus spp         |                                   | 20                      | Ampicillin              | 13                 | 65.00              | 3              | 15.00          | 4                 | 20.00             |
|                         |                                   |                         | Ampicillin/sulbactam    | 14                 | 70.00              | 1              | 5.00           | 5                 | 25.00             |
|                         |                                   |                         | Azithromycin            | 15                 | 75.00              | 0              | 0.00           | 5                 | 25.00             |
|                         |                                   |                         | Ceftriaxone             | 13                 | 65.00              | 0              | 0.00           | 7                 | 35.00             |
|                         |                                   |                         | Cefuroxime              | 13                 | 65.00              | 1              | 5.00           | 6                 | 30.00             |
|                         |                                   |                         | Co-trimoxazole          | 6                  | 30.00              | 9              | 45.00          | 5                 | 25.00             |
| Klebsiella spp          |                                   | 5                       | Amikacin                | 3                  | 60.00              | 0              | 0.00           | 2                 | 40.00             |
|                         |                                   |                         | Ampicillin/sulbactam    | 3                  | 60.00              | 0              | 0.00           | 2                 | 40.00             |
|                         |                                   |                         | Cefepime                | 3                  | 60.00              | 0              | 0.00           | 2                 | 40.00             |
|                         | Ceftazidime                       |                         | 4                       | 80.00              | 0                  | 0.00           | 1              | 20.00             |                   |
|                         | Ciprofloxacin                     |                         | 3                       | 60.00              | 0                  | 0.00           | 2              | 40.00             |                   |
|                         | Imipenem                          |                         | 3                       | 60.00              | 0                  | 0.00           | 2              | 40.00             |                   |
| Moraxella spp           | 7                                 | Amoxicillin/clavulanate | 4                       | 57.14              | 0                  | 0.00           | 3              | 42.86             |                   |
|                         |                                   | Ampicillin              | 0                       | 0.00               | 5                  | 71.43          | 2              | 28.57             |                   |
|                         |                                   | Ampicillin/sulbactam    | 5                       | 71.43              | 1                  | 14.29          | 1              | 14.29             |                   |
|                         |                                   | Azithromycin            | 6                       | 85.71              | 0                  | 0.00           | 1              | 14.29             |                   |
|                         |                                   | Cefuroxime              | 6                       | 85.71              | 0                  | 0.00           | 1              | 14.29             |                   |
| Pseudomonas spp         | 35                                | Amikacin                | 11                      | 31.43              | 6                  | 17.14          | 18             | 51.43             |                   |
|                         |                                   | Cefepime                | 27                      | 77.14              | 3                  | 8.57           | 5              | 14.29             |                   |
|                         |                                   | Ceftazidime             | 31                      | 88.57              | 1                  | 2.86           | 3              | 8.57              |                   |
|                         |                                   | Ciprofloxacin           | 21                      | 60.00              | 4                  | 11.43          | 10             | 28.57             |                   |
|                         |                                   | Gentamicin              | 16                      | 45.71              | 8                  | 22.86          | 11             | 31.43             |                   |

---

|                         |    |       |   |      |    |       |
|-------------------------|----|-------|---|------|----|-------|
| Imipenem                | 20 | 57.14 | 1 | 2.86 | 14 | 40.00 |
| Meropenem               | 26 | 74.29 | 1 | 2.86 | 8  | 22.86 |
| Piperacillin/tazobactam | 25 | 71.43 | 2 | 5.71 | 8  | 22.86 |

---

Table 4 Classification of the genetic variants found among Ecuadorian children with CF

| identification     | Nucleotide identification | Protein identification (change) | dbSNP ID     | Clinical Significance | Molecular consequence   | Class of allele mutation | Clinical classification | CFTR 2 database patient reports |
|--------------------|---------------------------|---------------------------------|--------------|-----------------------|-------------------------|--------------------------|-------------------------|---------------------------------|
| ∫G>A               | -                         | -                               | Not reported | Not reported          | Not reported            | Non classified           | Non classified          | Not reported                    |
| ∫G>C               | -                         | -                               | Not reported | Not reported          | Not reported            | Non classified           | Non classified          | Not reported                    |
| ∫G>C               | -                         | -                               | Not reported | Not reported          | Not reported            | Non classified           | Non classified          | Not reported                    |
| ∫G>T               | -                         | -                               | Not reported | Not reported          | Not reported            | Non classified           | Non classified          | Not reported                    |
| ∫A>G               | -                         | -                               | Not reported | Not reported          | Not reported            | Non classified           | Non classified          | Not reported                    |
| ∫T>C               | c.164+12T>C               | -                               | rs121908790  | Uncertain             | Intron variant          | Non classified           | Non classified          | Not reported                    |
| ∫A>G               | -                         | -                               | Not reported | Not reported          | Not reported            | Non classified           | Non classified          | Not reported                    |
| ∫G>A               | c.254G>A                  | p.Gly85Glu (G85E)               | rs75961395   | Pathogenic            | Missense variant        | Class II                 | A group                 | 584                             |
| ∫G>A               | c.509G>A                  | p.Arg170His (R170H)             | rs1800079    | Pathogenic            | Missense variant        | Non classified           | Non classified          | 11                              |
| ∫G>T               | c.489+1G>T                | 621+1G>T                        | rs78756941   | Pathogenic            | Splice donor variant    | Class I                  | A group                 | 1,293                           |
| ∫G>C               | c.1624G>T                 | p.Gly542Ter (G542X)             | rs113993959  | Pathogenic            | Nonsense variant        | Class I                  | A group                 | 3,489                           |
| ∫C>T               | c.869+11C>T               | -                               | rs1800503    | Benign                | Intron variant          | Non classified           | Non classified          | Not reported                    |
| ∫G>T               | c.988G>T                  | p.Gly330Ter (G330*)             | rs79031340   | Pathogenic            | Nonsense variant        | Non classified           | Non classified          | 23                              |
| ∫A>G               | c.1408=                   | p.Val470= (M470V)               | rs213950     | Benign                | Missense variant        | Non classified           | C group                 | 209                             |
| ∫_98811delTCT      | c.1521_1523del            | p.Phe508del (F508del)           | rs113993960  | Pathogenic            | Inframe variant         | Class II                 | A group                 | 65,046                          |
| ∫0A>G              | c.1826A>G                 | p.His609Arg (H609R)             | rs397508310  | Pathogenic            | Missense variant        | Non classified           | Non classified          | 9                               |
| ∫2218_117592219dup | c.2052dupA                | p.Gln685fs (Gln685Thrfs)        | rs121908746  | Pathogenic            | frameshift variant      | Non classified           | Non classified          | 324                             |
| ∫2382del           | c.2215del                 | p.Val739fs (2347delG)           | rs397508353  | Pathogenic            | Frameshift variant      | Non classified           | Non classified          | 38                              |
| ∫8T>G              | c.2562T>G                 | p.Thr854= (T854T)               | rs1042077    | Benign                | Synonymous variant      | Non classified           | Non classified          | 36                              |
| ∫9 G>A             | c.2908G>A                 | p.Gly970Ser (G970S)             | rs397508453  | Uncertain             | Missense variant        | Non classified           | Non classified          | 10                              |
| ∫8G>T              | -                         | -                               | Not reported | Not reported          | Not reported            | Non classified           | Non classified          | Not reported                    |
| ∫8T>A              | -                         | -                               | Not reported | Not reported          | Not reported            | Non classified           | Non classified          | Not reported                    |
| ∫T>C               | c.3294G>A                 | p.Trp1098Ter (W1098X)           | rs397508533  | Pathogenic            | Nonsense variant        | Non classified           | Non classified          | 9                               |
| ∫7A>G              | c.3870A>G                 | p.Pro1290= (P1290P)             | rs1800130    | Benign                | Synonymous variant      | Non classified           | Non classified          | Not reported                    |
| ∫4C>G              | c.3909C>G                 | p.Asn1303Lys (N1303K)           | rs80034486   | Pathogenic            | Missense variant        | Class II                 | A group                 | 2,147                           |
| ∫9A>C              | -                         | -                               | Not reported | Not reported          | Not reported            | Non classified           | Non classified          | Not reported                    |
| ∫9G>A              | c.1680-1G>A               | 1812-1G>A                       | rs121908794  | Pathogenic            | Splice acceptor variant | Non classified           | Non classified          | 31                              |
| ∫1 G>A             | c.4387C>T                 | p.Gln1463Ter (Q1463*)           | rs886044425  | Uncertain             | Nonsense variant        | Non classified           | Non classified          | Not reported                    |
| ∫9C>A              | -                         | -                               | Not reported | Not reported          | Not reported            | Non classified           | Non classified          | Not reported                    |

Table 5 Molecular findings among pediatric patients diagnosed with CF in a tertiary level hospital in Ecuador

| Genetic identification   | Nucleotide identification | Protein identification (change) | Number of reports | Heterozygosis | Homozygosis |
|--------------------------|---------------------------|---------------------------------|-------------------|---------------|-------------|
| g.19395G>A               | -                         | -                               | 2                 | -             | 2           |
| g.43555G>C               | -                         | -                               | 1                 | 1             | -           |
| g.43575G>C               | -                         | -                               | 1                 | 1             | -           |
| g.43580G>T               | -                         | -                               | 1                 | 1             | -           |
| g.43583A>G               | -                         | -                               | 1                 | 1             | -           |
| g.43592T>C               | c.164+12T>C               | -                               | 2                 | 2             | -           |
| g.43594A>G               | -                         | -                               | 1                 | 1             | -           |
| g.48340G>A               | c.254G>A                  | p.Gly85Glu (G85E)               | 4                 | 4             | -           |
| g.73512G>A               | c.509G>A                  | p.Arg170His (R170H)             | 1                 | 1             | -           |
| g.70332G>T               | c.489+1G>T                | 621+1G>T                        | 1                 | 1             | -           |
| g.74534G>C               | c.1624G>T                 | p.Gly542Ter (G542X)             | 2                 | 2             | -           |
| g.206154C>T              | c.869+11C>T               | -                               | 4                 | 3             | 1           |
| g.79435G>T               | c.988G>T                  | p.Gly330Ter (G330*)             | 1                 | -             | 1           |
| g.98696A>G               | c.1408=                   | p.Val470= (M470V)               | 6                 | 3             | 3           |
| g.98808_98811delTCT      | c.1521_1523del            | p.Phe508del (F508del)           | 19                | 15            | 4           |
| g.131210A>G              | c.1826A>G                 | p.His609Arg (H609R)             | 13                | 11            | 2           |
| g.117592218_117592219dup | c.2052dupA                | p.Gln685fs (Gln685Thrfs)        | 1                 | 1             | -           |
| g.117592382del           | c.2215del                 | p.Val739fs (2347delG)           | 1                 | 1             | -           |
| g.134218T>G              | c.2562T>G                 | p.Thr854= (T854T)               | 1                 | 1             | -           |
| g.142999 G>A             | c.2908G>A                 | p.Gly970Ser (G970S)             | 1                 | 1             | -           |
| g.143018G>T              | -                         | -                               | 1                 | 1             | -           |
| g.149918T>A              | -                         | -                               | 1                 | 1             | -           |
| g.74629T>C               | c.3294G>A                 | p.Trp1098Ter (W1098X)           | 3                 | 3             | -           |
| g.181807A>G              | c.3870A>G                 | p.Pro1290= (P1290P)             | 1                 | 1             | -           |
| g.192094C>G              | c.3909C>G                 | p.Asn1303Lys (N1303K)           | 4                 | 4             | -           |
| g.204099A>C              | -                         | -                               | 7                 | -             | 7           |
| g.129569G>A              | c.1680-1G>A               | 1812-1G>A                       | 1                 | 1             | -           |
| g.206271 G>A             | c.4387C>T                 | p.Gln1463Ter (Q1463*)           | 2                 | 2             | -           |
| g.206359C>A              | -                         | -                               | 4                 | -             | 4           |

Table 6 Predisposing genetic factors in CF positive cases in a cohort of Ecuadorian children attending the HECAM hospital

| Patient ID     | Mutation      | State        | Age group         | Z Score (mean) | Sweat test (mean) | Prevalent bacteria                          | Fev1 (mean)               | FVC (mean) | Fev1% (mean) | Hospital Admissions | Inpatient days |
|----------------|---------------|--------------|-------------------|----------------|-------------------|---|---------------------------|------------|--------------|---------------------|----------------|
| All population | Table 4 and 5 |              | 9,2 (mean)        | -0,62          | 96,78             | Table 3                                     | 90,45                     | 98,78      | 87,73        | 2,5 (mean)          | 18 (mean)      |
| 3              | H609R         | Heterozygous | 5 to 10 years     | 1              | 120               | Staphylococcus aureus oxacillin resistant   | 105,22                    | 104,42     | 99,38        | -                   | -              |
|                | c.204099A>C   | Homozygous   |                   |                |                   |   |                           |            |              |                     |                |
| 10             | c.19395G>A    | Homozygous   | 10 to 15 years    | -3,15          | 110,5             | Staphylococcus aureus oxacillin susceptible | 91,52                     | 96,45      | 93,45        | -                   | -              |
|                | M470V         | Homozygous   |                   |                |                   |   |                           |            |              |                     |                |
|                | H609R         | Homozygous   |                   |                |                   |   |                           |            |              |                     |                |
|                | c.204099A>C   | Homozygous   |                   |                |                   |   |                           |            |              |                     |                |
| 14             | F508del       | Heterozygous | 10 to 15 years    | -1,18          | 118               | Staphylococcus aureus oxacillin resistant   | 67,45                     | 73,35      | 78,13        | 3                   | 18             |
|                | W1098X        | Heterozygous |                   |                |                   |   |                           |            |              |                     |                |
|                | c.204099A>C   | Homozygous   |                   |                |                   |   |                           |            |              |                     |                |
|                | c.206359C>A   | Homozygous   |                   |                |                   |   |                           |            |              |                     |                |
|                | c.43555G>C    | Heterozygous |                   |                |                   |   |                           |            |              |                     |                |
|                | c.43592T>C    | Heterozygous |                   |                |                   |   |                           |            |              |                     |                |
| c.869+11C>T    | Heterozygous  |              |                   |                |                   |   |                           |            |              |                     |                |
| 17             | T854T         | Homozygous   | Less than 5 years | 0,26           | 87                | Staphylococcus aureus oxacillin resistant   | Patient less than 5 years |            |              | -                   | -              |
|                | c.204099A>C   | Homozygous   |                   |                |                   |   |                           |            |              |                     |                |
|                | R170H         | Heterozygous |                   |                |                   |   |                           |            |              |                     |                |
|                | G330E         | Homozygous   |                   |                |                   |   |                           |            |              |                     |                |
|                | Q1463Q        | Heterozygous |                   |                |                   |   |                           |            |              |                     |                |
| 25             | c.43580G>T    | Heterozygous | 10 to 15 years    | 0,05           | 86                | Staphylococcus aureus oxacillin resistant   | 93,15                     | 102,58     | 89,3         | 1                   | 21             |
|                | c.204099A>C   | Homozygous   |                   |                |                   |   |                           |            |              |                     |                |
|                | G85E          | Heterozygous |                   |                |                   |   |                           |            |              |                     |                |
|                | H609R         | Heterozygous |                   |                |                   |   |                           |            |              |                     |                |
|                | M470V         | Homozygous   |                   |                |                   |   |                           |            |              |                     |                |
|                | c.206359C>A   | Homozygous   |                   |                |                   |   |                           |            |              |                     |                |
|                | c.43583A>G    | Heterozygous |                   |                |                   |   |                           |            |              |                     |                |
|                | c.43594A>G    | Homozygous   |                   |                |                   |   |                           |            |              |                     |                |
|                | c.74629T>C    | Heterozygous |                   |                |                   |   |                           |            |              |                     |                |
| 41             | c.143018G>T   | Heterozygous | 5 to 10 years     | -0,54          | 83,5              | Moraxella spp                               | 93,9                      | 92,56      | 100,8        | -                   | -              |
|                | c.204099A>C   | Homozygous   |                   |                |                   |   |                           |            |              |                     |                |
|                | c.206359C>A   | Homozygous   |                   |                |                   |   |                           |            |              |                     |                |
|                | M470V         | Homozygous   |                   |                |                   |   |                           |            |              |                     |                |
|                | G970S         | Heterozygous |                   |                |                   |   |                           |            |              |                     |                |
| 45             | c.19395G>A    | Homozygous   | 10 to 15 years    | -2,16          | 67                | Staphylococcus aureus oxacillin susceptible | 72,28                     | 88,58      | 82,93        | -                   | -              |
|                | c.74534G>C    | Heterozygous |                   |                |                   |   |                           |            |              |                     |                |
|                | P1290P        | Heterozygous |                   |                |                   |   |                           |            |              |                     |                |
|                | M470V         | Heterozygous |                   |                |                   |   |                           |            |              |                     |                |
|                | Q1463Q        | Heterozygous |                   |                |                   |   |                           |            |              |                     |                |
| 46             | c.204099A>C   | Homozygous   | Less than 5 years | 0,33           | 84,5              | Haemophilus spp                             | Patient less than 5 years |            |              | -                   | -              |
|                | c.206359C>A   | Homozygous   |                   |                |                   |   |                           |            |              |                     |                |
|                | M470V         | Heterozygous |                   |                |                   |   |                           |            |              |                     |                |

## Figures




Figure 1

Spirometry results from baseline up to 9 months follow-up in patients from Ecuador. \* FEV1/FVC is measured in percentage, while FVC and FEV1 are expressed in percentage of the predicted value.




Figure 2

Presence of different microorganism per age group according to the bacteriological culture results